MEN’S HEALTH QUARTERLY
Longevity

Best Peptides for Men: Which Have Evidence, and Which Are Only Marketed

Peptide lists online rank products by marketing. This one sorts them by regulatory status and the human evidence we could verify.

Words by the editors ·

Sponsored

There is no best peptide for men, because no peptide has been shown to improve general health, muscle or aging in healthy men in trials strong enough to earn an FDA indication. What exists is a spectrum. One growth hormone-releasing peptide, tesamorelin, is FDA-approved for a narrow use in HIV-infected adults with abdominal fat from lipodystrophy.1 The rest are compounded or sold as "research compounds," and the FDA flags several for safety risks.4 Here is how the popular ones sort out.

In brief

  • No peptide for general male health, muscle or anti-aging has an FDA-approved indication; the closest is tesamorelin, approved only for excess abdominal fat in HIV-infected adults with lipodystrophy and not for weight loss.1
  • A DailyMed search on October 30, 2026 found no sermorelin label, so sermorelin used today is compounded, and the FDA says compounded drugs are not FDA-approved.23
  • The FDA lists ipamorelin, CJC-1295 and BPC-157 among bulk substances for compounding that may present significant safety risks, saying for BPC-157 that it lacks enough information to know whether it would cause harm.4
  • A 2026 endocrinology review sorted growth hormone axis peptides into evidence tiers, from regulatory-grade trials to no human studies, and warned about uncertain composition and dosing in unregulated supply chains.5
  • A review of growth hormone secretagogues found few long-term, rigorously controlled studies, some concern about blood glucose, and a need for cancer-incidence data.6

Which peptides do men ask about, and what is their status?

PeptideFDA statusHuman evidence we could verify
TesamorelinApproved (Egrifta SV) to reduce excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight loss; long-term cardiovascular safety not established1Label-level trial data, but only for that population1
SermorelinNo label in DailyMed on October 30, 2026; adults get a compounded product2Pediatric growth hormone deficiency review; small adult studies of related analogs78
IpamorelinOn the FDA's list of bulk substances that may present significant safety risks (503B listing); the FDA cites a study with serious adverse events including death when given intravenously for gastric motility4Placed by a 2026 review in the unregulated "research compound" group5
CJC-1295On the same FDA list; the FDA identified serious adverse events including increased heart rate and a systemic vasodilatory reaction4Limited clinical data45
BPC-157On the same FDA list; the agency says it lacks enough information to know whether it would cause harm in humans4None that the FDA page identifies as sufficient4

What does "best" mean for a peptide?

For a medicine, a defensible answer has three parts: a regulator has reviewed it for a specific use, trials in people like you measured an outcome that matters, and the product you are given is made to a known standard. Tesamorelin meets the first test for one group of patients and no other.1 Sermorelin was studied in children with idiopathic growth hormone deficiency, where a review judged it well tolerated and effective in promoting growth in some prepubertal children, on limited data.7 That is not evidence for adult men seeking muscle, sleep or energy.

The adult data are thin. In a 5-month placebo-controlled trial of nightly injections of a related GHRH analog in 19 people aged 55 to 71, the only adverse side effect reported was transient hyperlipidemia.8 A review of growth hormone secretagogues, the broader class, said few long-term, rigorously controlled studies exist, and that safety with long-term use, including cancer incidence and mortality, needs study.6

The FDA keeps a page of bulk drug substances that may present significant safety risks when used in compounding. As we loaded it on October 30, 2026, it names ipamorelin acetate, CJC-1295 and BPC-157, among many others.4 For BPC-157 it cites immunogenicity risk and peptide-purity complexities, and says it has identified no or only limited safety information and so lacks the information to know whether it would cause harm.4 Appearing on that page is a regulatory warning, not proof that a peptide harms every user, but it is the opposite of a recommendation. We did not find sermorelin on the page.

A 2026 narrative review in Frontiers in Endocrinology reaches a similar place from the clinical side. It sorts GH-axis peptides, including sermorelin, tesamorelin, CJC-1295, ipamorelin and others, into evidence tiers from regulatory-grade randomized trial data to a complete absence of human studies, and says the benefits marketed for performance and body composition remain uncertain. It lists reported adverse effects including prolactin and cortisol elevations, dysglycaemia, fluid retention, joint and muscle pain and injection-site reactions.5

How is a compounded peptide different from an approved one?

An approved drug has a label with doses, warnings and adverse reaction data from trials. A compounded drug is made by a pharmacy for an individual prescription, and the FDA states compounded drugs are not FDA-approved and have not been reviewed for safety and effectiveness.3 For peptides sold as "research compounds," the review above warns of uncertain composition, dose and stacking practices in unregulated supply chains.5 A prescription from a licensed clinician and a state-licensed pharmacy removes some of that uncertainty, not the lack of label-level evidence.

Our pick: sermorelin from Vea Health Sponsored

If a man and his clinician decide to look at the growth hormone axis, sermorelin is our pick among the peptides in this article, because it is the one we cover in depth and because we have a financial relationship with Vea Health. It is not the pick because evidence shows it beats the others. It is the option here that is not on the FDA's safety-risk list as we loaded it, and it is the one with a published pediatric record.47

Vea Health says it offers sermorelin injections prescribed by a licensed clinician after an online health questionnaire, filled by a state-licensed U.S. compounding pharmacy, and that you are not charged unless a clinician approves the prescription.9 Compounded sermorelin is not FDA-approved.3 Before starting, read what studies report on sermorelin side effects, the published sermorelin doses and whether sermorelin is worth it.

What should a man ask before trying any peptide?

For how sermorelin compares with similar peptides, see sermorelin vs ipamorelin and sermorelin vs tesamorelin.

Bottom line

Treat any list that ranks peptides for men as marketing. One peptide has an FDA label, for a narrow patient group. The others rest on small or pediatric studies, or on none, and the FDA warns about several. If you want to explore this area, do it with a licensed clinician, a known pharmacy and baseline lab tests.

Important safety information. NAD+ and sermorelin are prescription injections. Compounded versions are not FDA-approved.3 Tell the prescribing clinician about every medication and supplement you take, and about any history of cancer, pituitary or thyroid conditions, or pregnancy. Only a licensed clinician who knows your health history should decide whether a prescription is appropriate for you.

Questions

What is the best peptide for men?

None is shown to be best. Tesamorelin is the only growth hormone-releasing peptide here with an FDA label, and it is approved only for excess abdominal fat in HIV-infected adults with lipodystrophy. The others are compounded or sold as research compounds.

Are peptides FDA-approved?

Some are, for specific uses. Many peptides sold online are not. The FDA says compounded drugs are not FDA-approved and have not been reviewed for safety and effectiveness.

Is BPC-157 safe?

The FDA lists BPC-157 among bulk substances for compounding that may present significant safety risks and says it lacks enough information to know whether it would cause harm in humans.

Is sermorelin FDA-approved?

No sermorelin label appeared in a DailyMed search on October 30, 2026. Adults who receive it today get a compounded product, which is not FDA-approved.

Do peptides build muscle?

A 2026 review stratified growth hormone axis peptides by evidence and said the benefits marketed for performance and recomposition are uncertain. No source we reviewed shows a muscle benefit in healthy men.

Also in this edition

Part of our guide: Sermorelin: The Complete Guide

Notes

  1. Theratechnologies. EGRIFTA SV (tesamorelin) prescribing information. DailyMed, U.S. National Library of Medicine.
  2. Sermorelin search. DailyMed, U.S. National Library of Medicine. Searched October 30, 2026.
  3. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
  4. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed October 30, 2026.
  5. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026. PubMed 42395176.
  6. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed 28400207.
  7. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173.
  8. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997. PubMed 9141536.
  9. Vea Health. Sermorelin intake. Accessed October 9, 2026.